BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/21/2019 6:46:23 AM | Browse: 676 | Download: 1372
Publication Name World Journal of Clinical Oncology
Manuscript ID 46830
Country/Territory Türkiye
Received
2019-02-26 02:15
Peer-Review Started
2019-02-27 11:26
To Make the First Decision
2019-04-12 00:28
Return for Revision
2019-04-24 07:27
Revised
2019-05-05 16:15
Second Decision
2019-07-26 10:05
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2019-07-30 18:01
Articles in Press
2019-07-30 18:01
Publication Fee Transferred
Edit the Manuscript by Language Editor
2019-08-09 18:53
Typeset the Manuscript
2019-08-21 00:50
Publish the Manuscript Online
2019-08-21 06:46
ISSN 2218-4333 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019 Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Retrospective Study
Article Title Prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer
Manuscript Source Invited Manuscript
All Author List Gokhan Ozyigit, Pervin Hurmuz, Deniz Yüce and Fadıl Akyol
ORCID
Author(s) ORCID Number
Gokhan Ozyigit http://orcid.org/0000-0002-7497-4348
Pervin Hurmuz http://orcid.org/0000-0003-1221-9192
Deniz Yüce http://orcid.org/0000-0003-0725-5447
Fadıl Akyol http://orcid.org/0000-0002-5287-3474
Funding Agency and Grant Number
Corresponding Author Gokhan Ozyigit, MD, Chairman, Full Professor, Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara 06100, Türkiye. gozyigit@hacettepe.edu.tr
Key Words Prostate cancer; Androgen deprivation therapy; Radiotherapy; Testosterone; Castration;
Core Tip Castrate testosterone level of less than 20 ng/dL achieved after primary radiotherapy plus androgen deprivation treatment for non-metastatic prostate cancer is associated with better biochemical relapse free survival. Testosterone level of < 50 ng/dL has been used to define castrate level after surgery or after androgen deprivation treatment in metastatic prostate cancer (PC). In this study, we evaluated the effect of two different castrate testosterone levels, < 50 and < 20 ng/dL, on biochemical relapse free survival in patients with non-metastatic intermediate and high risk PC receiving definitive modern radiotherapy and androgen deprivation treatment. With a median follow up of 125 mo we found that castrate testosterone level of less than 20 ng/dL achieved after primary radiotherapy plus androgen deprivation treatment was found to be associated with better biochemical relapse free survival.
Publish Date 2019-08-21 06:46
Citation Ozyigit G, Hurmuz P, Yuce D, Akyol F. Prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer. World J Clin Oncol 2019; 10(8): 283-292 URL: https://www.wjgnet.com/2218-4333/full/v10/i8/283.htm DOI: https://dx.doi.org/10.5306/wjco.v10.i8.283
URL https://www.wjgnet.com/2218-4333/full/v10/i8/283.htm
DOI https://dx.doi.org/10.5306/wjco.v10.i8.283
Full Article (PDF) WJCO-10-283.pdf
Full Article (Word) WJCO-10-283.docx
Manuscript File FP6952_ce25_CE1MS-edit2.doc
Answering Reviewers 46830-Answering reviewers.pdf
Audio Core Tip 46830-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 46830-Conflict-of-interest statement.pdf
Copyright License Agreement 46830-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s) 46830-Informed consent statement.pdf
Institutional Review Board Approval Form or Document 46830-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate 46830-Language certificate.pdf
Peer-review Report 46830-Peer-review(s).pdf
Scientific Misconduct Check 46830-Scientific misconduct check.pdf
Scientific Editor Work List 46830-Scientific editor work list.pdf